The U.S. life sciences real estate market is entering a stabilization phase after two years of oversupply and declining rents, according to new data from Cushman & Wakefield. Asking rents at life sciences facilities averaged $64.17 per square foot in the second quarter of 2026, representing a 5.3 percent decline from the prior year. Yet the trajectory is beginning to shift as construction pipelines shrink and funding conditions improve for biotech and pharmaceutical companies.
The life sciences sector faced severe headwinds starting in 2024. A wave of speculative development during the pandemic boom created excess inventory across major hub markets. Boston, San Francisco, San Diego, and the Research Triangle saw particular strain as landlords competed for tenants and absorbed significant vacancy rates. Rents compressed across the board. Many Class A facilities that commanded premium pricing suddenly competed with newly delivered space, forcing price adjustments downward.
What changes now. The construction pipeline has contracted sharply. Developers pulled back on new projects as lending conditions tightened and landlords recognized the oversupply problem. Fewer completions mean less new inventory hitting the market. This dynamic allows existing stock to absorb current demand without fresh pressure on rents.
Funding conditions also improved entering 2026. After venture capital dried up in 2023 and 2024, biotech and pharmaceutical companies regained access to growth capital. This restored tenant demand for lab and research space. Life sciences companies that had deferred relocations or expansions began moving forward with leasing decisions. Landlords reported upticks in tenant inquiries across primary markets.
The recovery remains uneven by geography. Boston maintains stronger fundamentals than San Francisco, where life sciences real estate faces additional competition from tech office conversions and broader tech sector uncertainty. San Diego's market stabilizes as major pharma employers maintain steady operations. Secondary markets in North Carolina, Pennsylvania, and Colorado show different dynamics based on local tenant bases and vacancy conditions.
Landlords adapted in 2025 and early 2026. Many offered lease concessions, reduced asking rents, and tenant improvement allowances to maintain occupancy. Some converted excess ground floor retail into collaborative workspace or ancillary uses. Class B and C assets suffered more than Class A, as tenants prioritized state-of-the-art facilities with modern infrastructure.
For landlords owning stabilized assets in strong submarkets, 2026 offers a reset opportunity. The rent compression bottom appears near. Improved funding access strengthens tenant credit quality. Reduced construction pipelines limit future supply additions. These factors support rent stability through 2026 and potential modest growth in 2027 as supply and demand rebalance.
Tenants currently negotiate from a position of strength but face narrowing windows. Landlords who built excess concessions into recent deals now hesitate to extend those terms. Rents may hold flat or increase modestly, reducing the incentive to relocate. Tenants seeking expansion space should move forward with active negotiations before landlords tighten lease terms.
The message from Cushman & Wakefield: oversupply gives way to stabilization. The life sciences sector does not return to pandemic-era pricing and premium lease terms anytime soon. Market fundamentals improve enough to support current rent levels and prevent further deterioration. For investors, this stabilization translates to stabilized cash flows rather than growth plays.